NO20023879D0 - Partielle fettsyre-oksydasjonsinhibitorer i behandlingen av kongestiv hjertesvikt - Google Patents

Partielle fettsyre-oksydasjonsinhibitorer i behandlingen av kongestiv hjertesvikt

Info

Publication number
NO20023879D0
NO20023879D0 NO20023879A NO20023879A NO20023879D0 NO 20023879 D0 NO20023879 D0 NO 20023879D0 NO 20023879 A NO20023879 A NO 20023879A NO 20023879 A NO20023879 A NO 20023879A NO 20023879 D0 NO20023879 D0 NO 20023879D0
Authority
NO
Norway
Prior art keywords
treatment
fatty acid
heart failure
congestive heart
acid oxidation
Prior art date
Application number
NO20023879A
Other languages
English (en)
Norwegian (no)
Other versions
NO20023879L (no
Inventor
Andrew A Wolff
Brent K Blackburn
Hani Naief Sabbah
William Clark Stanley
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of NO20023879L publication Critical patent/NO20023879L/no
Publication of NO20023879D0 publication Critical patent/NO20023879D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20023879A 2000-02-18 2002-08-15 Partielle fettsyre-oksydasjonsinhibitorer i behandlingen av kongestiv hjertesvikt NO20023879D0 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18356000P 2000-02-18 2000-02-18
US21990800P 2000-07-21 2000-07-21
PCT/US2001/004887 WO2001060348A2 (en) 2000-02-18 2001-02-15 Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure

Publications (2)

Publication Number Publication Date
NO20023879L NO20023879L (no) 2002-08-15
NO20023879D0 true NO20023879D0 (no) 2002-08-15

Family

ID=26879274

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20023879A NO20023879D0 (no) 2000-02-18 2002-08-15 Partielle fettsyre-oksydasjonsinhibitorer i behandlingen av kongestiv hjertesvikt

Country Status (17)

Country Link
US (2) US6528511B2 (zh)
EP (2) EP1259230A2 (zh)
JP (1) JP2004505886A (zh)
KR (1) KR20020075801A (zh)
CN (1) CN1227004C (zh)
AR (1) AR033510A1 (zh)
AU (1) AU778203B2 (zh)
BR (1) BR0108452A (zh)
CA (1) CA2398691A1 (zh)
HK (1) HK1048250A1 (zh)
IL (1) IL151014A0 (zh)
MX (1) MXPA02007639A (zh)
NO (1) NO20023879D0 (zh)
NZ (1) NZ520780A (zh)
TW (1) TWI235655B (zh)
WO (1) WO2001060348A2 (zh)
ZA (1) ZA200206451B (zh)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02007639A (es) * 2000-02-18 2004-08-23 Cv Therapeutics Inc Inhibidores de la oxidacion parcial de los acidos grasos en el tratamiento de la falla cardiaca congestiva.
WO2003037323A2 (en) * 2001-10-26 2003-05-08 MEDIGENE AG Gesellschaft für Molekularbiologische Kardiologie und Onkologie Inhibitors of the fatty acid oxidation for prophylaxis and treatment of diseases related to mitochondrial dysfunction
US8460693B2 (en) * 2001-11-08 2013-06-11 Atrium Medical Corporation Intraluminal device with a coating containing synthetic fish oil and a therapeutic agent
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US20040063717A1 (en) * 2002-05-21 2004-04-01 Andrew Wolff Method of treating diabetes
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
AU2003300827B2 (en) * 2002-12-05 2009-08-13 Gilead Palo Alto, Inc. Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
CA2550257A1 (en) * 2003-12-18 2005-07-07 Cv Therapeutics, Inc. 1-akan-2-ol substituted piperazine and piperidine compounds
JP2007530543A (ja) † 2004-03-22 2007-11-01 オシリス セラピューティクス，インコーポレイテッド 間葉幹細胞及びその使用法
US9801982B2 (en) * 2004-09-28 2017-10-31 Atrium Medical Corporation Implantable barrier device
US20060067977A1 (en) * 2004-09-28 2006-03-30 Atrium Medical Corporation Pre-dried drug delivery coating for use with a stent
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US9012506B2 (en) * 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US8367099B2 (en) 2004-09-28 2013-02-05 Atrium Medical Corporation Perforated fatty acid films
US8312836B2 (en) 2004-09-28 2012-11-20 Atrium Medical Corporation Method and apparatus for application of a fresh coating on a medical device
EP1811935B1 (en) * 2004-09-28 2016-03-30 Atrium Medical Corporation Heat cured gel and method of making
US20090011116A1 (en) * 2004-09-28 2009-01-08 Atrium Medical Corporation Reducing template with coating receptacle containing a medical device to be coated
US20060083768A1 (en) * 2004-09-28 2006-04-20 Atrium Medical Corporation Method of thickening a coating using a drug
AU2005304421A1 (en) * 2004-11-09 2006-05-18 Gilead Palo Alto, Inc. Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure
EP1865945A4 (en) * 2005-03-11 2008-05-21 Hong Kong Nitric Oxide Ltd TREATMENT COMBINATION FOR ENDOTHELIAL DISORDERS, ANGINA AND DIABETES
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
US8574627B2 (en) * 2006-11-06 2013-11-05 Atrium Medical Corporation Coated surgical mesh
AU2006304590A1 (en) * 2005-10-15 2007-04-26 Atrium Medical Corporation Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
US7606617B2 (en) * 2006-01-31 2009-10-20 Cardiac Pacemakers, Inc. Urinalysis for the early detection of and recovery from worsening heart failure
WO2008030581A1 (en) * 2006-09-08 2008-03-13 Symphony Medical, Inc. Intramyocardial patterning for treating localized anomalies of the heart
US9492596B2 (en) * 2006-11-06 2016-11-15 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
EP2117549A1 (en) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Use of ranolazine for the treatment of coronary microvascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
JP2010518181A (ja) 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 心血管疾患の処置のためのラノラジンの使用
WO2008101012A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of non-coronary microvascular diseases
US20080233191A1 (en) * 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
WO2008127607A2 (en) * 2007-04-11 2008-10-23 Henry Ford Health System Cardiac repair, resizing and reshaping using the venous system of the heart
KR20100033490A (ko) * 2007-05-31 2010-03-30 질레드 팔로 알토 인코포레이티드 상승된 뇌-형 나트륨이뇨 펩티드에 대한 라놀라진
CN101066253B (zh) * 2007-06-07 2011-01-05 北京本草天源药物研究院 一种雷诺嗪缓释片
WO2008154033A2 (en) * 2007-06-11 2008-12-18 Symphony Medical, Inc. Cardiac patterning for improving diastolic function
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
EA201070914A1 (ru) * 2008-02-06 2011-04-29 Гайлид Сайэнсиз, Инк. Применение ранолазина для лечения боли
JP2012526848A (ja) * 2009-05-14 2012-11-01 ギリアード サイエンシーズ， インコーポレイテッド Ｃｎｓ障害の治療のためのラノラジン
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
BR112012006433A2 (pt) * 2009-09-25 2016-04-19 Lupin Ltd composição de libertação sustentada de ranolazina
WO2012009707A2 (en) 2010-07-16 2012-01-19 Atrium Medical Corporation Composition and methods for altering the rate of hydrolysis of cured oil-based materials
EP2524688B1 (en) * 2011-05-11 2013-05-01 ratiopharm GmbH Composition for modified release comprising ranolazine
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
CN104758265B (zh) * 2014-01-07 2019-05-17 四川海思科制药有限公司 一种雷诺嗪缓释片药物组合物及其制备方法
FR3060567B1 (fr) 2016-12-19 2019-05-24 Ecole Normale Superieure De Lyon Substrat de glycosidase fluorogene et procede de detection associe
CN112438955A (zh) * 2019-08-30 2021-03-05 深圳翰宇药业股份有限公司 一种雷诺嗪缓释组合物及其制备方法
GR1010510B (el) * 2022-06-07 2023-07-20 Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, Στερεες φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης ρανολαζινης

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5001193A (en) 1988-12-22 1991-03-19 American Cyanamid Epoxy adhesive for bonding of automotive parts made from bulk or sheet molding compound containing polymeric toughening agent and Mannich Base
EP0714660B1 (en) 1989-06-23 2002-09-04 Syntex (U.S.A.) LLC Ranolazine and related piperazines for protecting skeletal muscles
US5455045A (en) 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
US6083532A (en) * 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
MXPA02007639A (es) * 2000-02-18 2004-08-23 Cv Therapeutics Inc Inhibidores de la oxidacion parcial de los acidos grasos en el tratamiento de la falla cardiaca congestiva.
AU3862301A (en) * 2000-02-22 2001-09-03 Cv Therapeutics Inc Substituted piperazine compounds

Also Published As

Publication number Publication date
HK1048250A1 (zh) 2003-03-28
EP2033633A2 (en) 2009-03-11
ZA200206451B (en) 2003-12-31
AU778203B2 (en) 2004-11-25
IL151014A0 (en) 2003-02-12
BR0108452A (pt) 2003-04-01
US20010047000A1 (en) 2001-11-29
CA2398691A1 (en) 2001-08-23
MXPA02007639A (es) 2004-08-23
TWI235655B (en) 2005-07-11
JP2004505886A (ja) 2004-02-26
US6677342B2 (en) 2004-01-13
CN1227004C (zh) 2005-11-16
US6528511B2 (en) 2003-03-04
AR033510A1 (es) 2003-12-26
EP1259230A2 (en) 2002-11-27
EP2033633A3 (en) 2009-07-08
CN1420766A (zh) 2003-05-28
US20030119718A1 (en) 2003-06-26
WO2001060348A3 (en) 2002-01-31
KR20020075801A (ko) 2002-10-05
NO20023879L (no) 2002-08-15
WO2001060348A2 (en) 2001-08-23
NZ520780A (en) 2006-04-28
AU4150501A (en) 2001-08-27

Similar Documents

Publication Publication Date Title
NO20023879D0 (no) Partielle fettsyre-oksydasjonsinhibitorer i behandlingen av kongestiv hjertesvikt
NO20031797L (no) Heteroarylalkylpiperazin-derivater som fettsyreoksidasjonsinhibitorer
DE60031710D1 (de) Fettsäurederivat zur behandlung von externen sekretionsstörungen
NO20030249D0 (no) Oksygenerte estere av 4-jod-fenylamino-benzohydroksamsyrer
ATE350375T1 (de) 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen
NO20000877D0 (no) Forbedret syrekorrosjonsinhibitor
NO20026008L (no) Fremgangsmåte for behandling av cardiovaskul¶re sykdommer
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
ATE546425T1 (de) Herstellung von (r)-2-alkyl-3-phenylpropionsäuren
NO20030295L (no) Anvendelse av derivater av valproinsyre- og 2- valproensyreamider for behandling av manier ved bipolare lidelser
ATE338027T1 (de) Herstellung von iminodiessigsäure-derivaten aus monoethanolamin-substraten
DE602004022034D1 (de) Herstellung von konjugierten linolsäuren und linolsäuresalzen
NO20024488L (no) Anvendelse av melkesyrebakterier for behandling av bukhinnebetennelse
DE60119076D1 (de) Gebrauch von Pyrometerdaten um Oxydation festzustellen
DE60143052D1 (de) Lipid vom carbonsäuretyp
NO20024236L (no) Behandling av psoriasis
DE60028816D1 (de) Herstellung von unipolaren Komponenten
DE60120990D1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
DE60010725T2 (de) Herstellung von arylcarbonsäureestern
DE60107191D1 (de) Herstellung von 2-Hydrocarbyl-2-Adamantylacrylaten
DE69934336D1 (de) Verwendung von halofuginone zur behandlung von urethralstriktur
DE60117846D1 (de) Herstellung von 6-aminocaprinsäurealkylestern
DE50012694D1 (de) Verwendung von fettsäurealkanolaminestern
EE200300013A (et) Bispidiini uued ühendid ning nende kasutamine südame arütmia ravis
NO20030762L (no) Forbedret spesifisitet i behandling av sykdommer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application